Notable Research Analysis: J.C. Penney Company, ParkerVision,, Pfizer Inc

Follow this company

Companies Mentioned

06/24/2014 [ACCESSWIRE]

NEW YORK / ACCESSWIRE / June 24, 2014 / Market Buzz Report, which provides up to date coverage, commentary and alerts on OTC and NASDAQ Stocks, issues critical stocks analysis for : J.C. Penney Company, ParkerVision,, Pfizer Inc.

J.C. Penney Company, Inc.(NYSE:JCP)’s shares fell 3.44% to $8.69. The company on June 23 announced that it has closed its new $2.35 billion asset-based senior secured credit facility, comprised of a $1.850 billion revolving line of credit and a $500 million term loan. The new facility replaces a $1.850 billion credit facility that was scheduled to mature in April 2016 and provides better pricing terms than the previous facility. Proceeds from the term loan will be used to pay down the cash borrowings on the previous facility. The revolving line of credit will be available for working capital and general corporate purposes.

Don’t Make the Mistake of Not Including This Undiscovered Social Media Gem In Your Portfolio? Read The Detailed Research Report Here (Or Copy & Paste Into Your Browser)

ParkerVision, Inc. (NASDAQ:PRKR)’s stock dropped 63.07% to $1.85. The company on June   announced that on Friday, June 20, United States District Judge Roy B. Dalton issued the following rulings related to outstanding motions in the ParkerVision v. Qualcomm patent infringement case: Qualcomm's Motion for Judgment as a Matter of Law and Motion for New Trial Regarding Invalidity was denied; Qualcomm's Renewed Motion for Judgment as a Mater of Law and Motion for New Trial Regarding Non-Infringement was granted; All other remaining motions were denied as moot.

FB Move Over there is a new social media stock in town. Read more here (Or Copy & Paste Into Your Browser)

Additionally, the company on June 13 announced that Petitions for Inter Partes Review of three of the company's patents were filed with the United States Patent and Trademark Office ("USPTO"). The petitions were filed by Michael Farmwald, admitted short-seller of the Company's stock, and RPX Corporation, requesting a review of ParkerVision patents 6,370,371, 6,266,518 and 6,061,551., Inc. (OTCMKTS:BNBI)’s  shares climbed 4.02% and closed at $1.81. The company on Apr. 3 announced that the Company has engaged IR Affiliates and for investor relations and market awareness. John Pentony, the President of IR Affiliates and will operate as investor relations for

Why Is It The Perfect Time To Buy BNBI? Get The Free Report Here (Or Copy & Paste Into Your Browser)

John Pentony of IR Affiliates and commented, "I am a believer in what James Palladino is doing at With all the Company has going on right now, I see so many ways my company's properties can work in concert with to the benefit of BNBI shareholders. I look forward to speaking to current and prospective shareholders."

Pfizer Inc. (NYSE:PFE)’s shares declined 1.11% and closed at $29.45. The company on June 8  announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine. ORAL Start is a 24-month Phase 3 study in patients with moderately to severely active rheumatoid arthritis who had not previously received methotrexate. The study showed that XELJANZ (tofacitinib citrate) 5 mg and 10 mg twice daily, as monotherapy (e.g., taken without methotrexate), inhibited the progression of structural damage and reduced the signs and symptoms of rheumatoid arthritis, and was statistically significantly superior to methotrexate on these measures at Month 6 (primary endpoint) and at all measured time points up to 24 months.

Is It The Perfect Time To Reshuffle Your Portfolio With This Revolutionary Social Media Play? Find Out Here (Or Copy & Paste Into Your Browser)

Additionally, the company on June 11 announced that over 10 abstracts have been accepted for presentation at the European League Against Rheumatism (EULAR) 2014 Annual Meeting (June 11-14, Paris, France), seven of which are focused on further characterizing the safety profile of XELJANZ (tofacitinib citrate) in treating moderately to severely active rheumatoid arthritis. is an investment community that focuses on MicroCap Securities. is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. does not have any position in any of the mentioned companies and has NO such intention to purchase any shares long or short in the open market over the next 72 hours. If you would like more information regarding our news coverage solutions, please visit for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at Follow us on Facebook: up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126 (SMS alerts are free, however data rates may apply, check your wireless plan for details.). 

SOURCE: Market Buzz Report 


Leave a comment...

Your Name